Eyeworld

49 EW FEATURE August 2016 • Presbyopia treatment Contact information Durrie: ddurrie@durrievision.com Waring: georgewaringiv@me.com Monovision changes "Most patients are good candidates for monovision," Dr. Waring said. As U.S. surgeons prepare to incor- porate presbyopic inlays into their treatment options, such treatments are expected to be used in place of monovision with growing frequency. "That's important because small aperture corneal inlays preserve stereo acuity, which is why patients who were not previously candi- dates for monovision may do well with this procedure," Dr. Waring said. "We typically do not per- form contact lens trials to simulate monovision because it takes 3 to 6 months for the brain to neuro-adapt to blended vision, so a short-term contact lens trial is not enough time to determine who is a candidate." Monovision screening includes determinations that patients have the potential for 20/20 or better uncorrected visual acuity in the dominant eye; confidence that good surgical results are likely; and the use of dominance testing. Inlays versus multifocals Another area where the DLS system is useful is in the explanation of the comparative benefits of inlays and multifocal IOLs, Dr. Durrie said. That is because corneal inlays require extremely good optics—espe- cially the KAMRA inlay (AcuFocus, Irvine, California)—because of the way the technology functions. That insight was provided by the clinical trials. "If you evaluate the lens and the lens does not have good optics—it is in stage 2 or stage 3 of DLS—then you need to move along to an IOL procedure," Dr. Durrie said. Although not available yet in the U.S., an IOL with an inlay (IC-8, AcuFocus) is available overseas. It is critical for patients to understand that presbyopia is a lens problem, that it has 3 stages, and they need to know what stage they are in. The DLS system helps them understand that, according to Dr. Durrie. "It's amazing watching patients' heads nod as they get it," Dr. Durrie said. "I've been in this field for many years, and this has been one of those breakthroughs in patient education that I think everyone should adopt." EW Editors' note: Dr. Durrie has financial interests with Abbott Medical Optics (Abbott Park, Illinois), AcuFocus, Alcon (Fort Worth, Texas), and Visiometrics. Dr. Waring has financial interests with Abbott Medical Optics, AcuFocus, and Visiometrics. Introducing the Visitec® FLACS Cannula Innovative tip design allows multi-use OVD Injections and other solutions Visitec Single Use Capsulorhexis forceps ● Blunt tips with wide platform for removing capsulotomies Designed to improve: ● Surgical effi ciency ● Clinical performance ● Patient safety Opening all femto incisions Check Capsulotomy Visit us at ESCRS Booth CN56 Call your local sales rep or BVI customer service at +44.1865.601256. Visit us at www.beaver-visitec.com Beaver-Visitec International, Sales Limited 85c Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY, UK BVI, BVI Logo and all other trademarks are property of Beaver-Visitec International (BVI) © 2016 BVI

• Cover